Early HIV-1 Envelope-specific Cytotoxic T Lymphocyte  Responses in Vertically Infected Infants by Pikora, Cheryl A. et al.
 
1153
 
J. Exp. Med. 
 
Ó
 
 The Rockefeller University Press • 0022-1007/97/04/1153/09 $2.00
Volume 185, Number 7, April 7, 1997 1153–1161
 
Early HIV-1 Envelope-speciﬁc Cytotoxic T Lymphocyte 
Responses in Vertically Infected Infants
 
By Cheryl A. Pikora,
 
*
 
 John L. Sullivan,
 
*
 
 Dennis Panicali,
 
‡
 
and Katherine Luzuriaga
 
*
 
From the 
 
*
 
Department of Pediatrics, Program in Molecular Medicine, University of Massachusetts 
Medical Center, Worcester, Massachusetts 01605; and 
 
‡
 
Therion Biologics Corporation, Cambridge, 
Massachusetts 02142
 
Summary
 
High frequencies of cytotoxic T lymphocyte precursors (CTLp) recognizing HIV-1 laboratory
strain gene products have been detected in adults within weeks of primary infection. In con-
trast, HIV-1–specific CTLp are uncommonly detected in infants younger than 6 mo. To ad-
dress the hypothesis that the use of target cells expressing laboratory strain 
 
env
 
 gene products
might limit the detection of HIV-1 env-specific CTLp in early infancy, recombinant vaccinia
vectors (vv) expressing HIV-1 
 
env
 
 genes from early isolates of four vertically infected infants
were generated. The frequencies of CTLp recognizing target cells infected with vv-expressing
 
env
 
 gene products from early isolates and HIV-1 IIIB were serially measured using limiting di-
lution followed by in vitro stimulation with mAb to CD3. In one infant, the detection of early
isolate env-specific CTLp preceded the detection of IIIB-specific CTLp. CTLp recognizing
HIV-1 IIIB and infant isolate 
 
env
 
 were detected by 6 mo of age in two infants. In a fourth in-
fant, HIV-1 IIIB 
 
env
 
 and early isolate 
 
env
 
-specific CTLp were simultaneously detected at 12 mo of
age. These results provide evidence that young infants can generate HIV-1–specific CTL re-
sponses and provide support for the concept of neonatal vaccination to prevent HIV-1 trans-
mission. However, the early predominance of type-specific CTL detected in some young in-
fants suggests that the use of vaccines based on laboratory strains of HIV-1 may not protect
against vertical infection.
 
T
 
he vertical transmission of HIV-1 from an infected
woman to her infant is the predominant mode of pe-
diatric infection. Prospective studies estimate the rate of
vertical transmission to be 14–40% (1). Vertical HIV-1 trans-
mission can occur in utero, during delivery (intrapartum), or
after birth through breastfeeding (1). In nonbreastfed popu-
lations, 45–70% of vertical infections occur in the intrapar-
tum period. In developing countries, where breastfeeding is
necessary and encouraged, up to 75% of infants may be in-
fected at or after delivery.
In recent years, the incidence of vertical HIV-1 trans-
mission has sharply increased (2) resulting in an urgent need
to develop effective strategies to prevent vertical HIV-1
infection. Although the administration of zidovudine to
mother–infant pairs has been shown to reduce significantly
the risk of vertical HIV-1 transmission (3), the cost and in-
tensity of the regimen render it impractical for use in de-
veloping nations, where most pediatric infections occur.
Additionally, perinatal antiretroviral therapy would not pre-
vent the vertical transmission of HIV-1 through breastfeed-
ing beyond the neonatal period. A safe and effective active/
passive vaccine regimen, begun at birth, therefore would
be a more attractive strategy. Better understanding of the
pathogenesis of vertical HIV-1 infection and the capability
of the young human infant to generate HIV-1–specific im-
mune responses is crucial for the development of a vaccine
to prevent vertical HIV-1 infection.
We and others have previously reported that HIV-1–spe-
cific cytotoxic T lymphocyte precursors (CTLp)
 
1
 
 are un-
commonly detected in early infancy (4, 5). Viral genotype/
phenotype, early viral load, host genotype, timing of infec-
tion, and history of prior infections appear to be important
factors in the generation of virus-specific CTL responses.
Two lines of evidence suggested to us that the use of lab-
strain vaccinia vectors (vv) to detect HIV-1–specific CTL
might underestimate the CTL repertoire in early infancy.
First, analysis of vertically transmitted HIV-1 env sequences
suggests that limited viral genotypes are transmitted or am-
plified after infection (6, 7). Second, Selin et al. (8) have re-
ported higher frequencies of lymphocytic choriomeningitis
(LCMV)–specific CTLp in animals who have experienced
prior heterologous viral infections than in immunologically
naive animals. Therefore, we hypothesized that type-spe-
cific responses might predominate in early infancy and that
 
1
 
Abbreviations used in this paper:
 
 CM, complete media; CTLp, cytotoxic T
lymphocyte precursors; LCMV, lymphocyte choriomeningitis; m.o.i.,
multiplicity of infection; vv, vaccinia vectors.
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the use of target cells expressing laboratory isolate gene prod-
ucts might limit the detection of HIV-1 env-specific CTLp
in early infancy.
To address this hypothesis, HIV-1 
 
env
 
 genes from early
isolates of four vertically infected infants were PCR ampli-
fied, cloned, and used to generate recombinant vv. CTLp
frequencies recognizing target cells infected with vv-express-
ing env gene products from early isolates and HIV-1 IIIB
were serially measured from early to late infancy using lim-
iting dilution followed by in vitro stimulation with mAb to
CD3; split-well analysis allowed the evaluation of cross-
reactivity of detected CTLp. In one infant, the detection of
CTLp recognizing target cells expressing early isolate 
 
env
 
preceded the detection of CTLp recognizing target cells
expressing IIIB env. These type-specific CTLp detected in
early infancy were later replaced by cross-reactive group-
specific CTL. Cross-reactive 
 
env
 
-specific CTLp recognizing
HIV-1 IIIB and infant isolate 
 
env
 
 were detected by 6 mo of
age in two infants. In a fourth infant, CTLp recognizing
target cells infected with HIV-1 IIIB 
 
env
 
 and early isolate
 
env
 
 were simultaneously detected at 12 mo of age. Implica-
tions for neonatal HIV-1 vaccine development are discussed.
 
Materials and Methods
 
Patients. 
 
Four infants with defined timing of infection and
previously characterized CTL responses to HIV-1 IIIB env (4)
were chosen for these studies. HIV-1 culture and DNA PCR
were positive in blood specimens obtained at birth and in all sub-
sequent specimens from two infants (VI-05 and VI-06), suggest-
ing in utero infection (9). HIV-1 culture and DNA PCR were
negative on specimens obtained from two other infants (VI-08
and VI-11) at birth but were positive by 1 mo of age, suggesting
late in utero or intrapartum infection. None of the infants were
on antiretroviral therapy at the time that isolates were obtained
for use in the preparation of vv constructs.
HIV-1 IIIB 
 
env
 
-specific CTLp were previously detected in
blood samples obtained during early infancy from only 1 (VI-06)
of the 4 infants (4). HIV-1 CTLp were detected in cord blood
and subsequent specimens from VI-06. HIV-1 gag-specific CTLp
were detected as early as 3 mo of age in VI-11; 
 
env
 
-specific CTLp
were not detected through 12 mo of age. In VI-05 and VI-08,
HIV-1 
 
env
 
-specific CTLp were not detected until 10–11 mo of
age. Human Studies Committee approval and individual in-
formed consent from the guardian of each infant were obtained
before we conducted these studies. Table 1 summarizes sequential
measures of peripheral blood HIV-1 load and CD4 counts of each
infant studied as well as the ages at which 
 
env
 
 genes were ampli-
fied from infant viral isolates for cloning and insertion into vv.
 
Lymphocyte Separation and Cryopreservation.
 
PBMC were iso-
lated from freshly drawn heparinized blood by Ficoll–Paque
(Pharmacia, Piscataway, NJ) density centrifugation (10). PBMC
were viably cryopreserved using a KRYO 10 Series cell freezer
and stored in liquid nitrogen until use.
 
Preparation of Genomic DNA.
 
PBMC cultures were performed
according to the AIDS Clinical Trials Group virology consensus
protocols (11). Supernatants from these cultures were used to es-
tablish low (1–2) passage viral cultures at the timepoints specified
in Table 1. In brief, 10
 
7
 
 HIV-1 seronegative donor PHA blasts
 
Table 1.
 
Sequential Measures of Peripheral Blood HIV-1 Load and CD4 Counts of Infants Studied
 
Patient Age DNA PCR Plasma culture
 
*
 
PBMC culture
 
‡
 
RNA
 
§
 
%CD4 Absolute CD4
VI-05 Birth Pos  0 0 ND 50 ND
 
1 mo
 
ND 1,562 625 2,533,526
2 mo ND  62 625 297,670 20 3,015
 
6 mo
 
ND ND ND ND 14 1,230
VI-06
 
Birth
 
Pos  0 25 49,000 ND ND
1.5 mo Pos  12.5 25 210,000 15 1,509
3 mo ND  62.5 125 340,000 19 1,369
5 mo  ND ND ND 1,300.000 25 1,110
VI-08 Birth Neg ND 0 ND 41 1,051
 
20 d
 
Pos  63 125 ND 50 2,090
1.5 mo ND ND ND 685,169 ND ND
5 mo Pos  0 1 321,712 36 2,547
 
6 mo
 
ND ND ND 57,302 ND ND
VI-11 Birth Neg  0 0 1,353 35 1,105
2 mo Pos ND 0 47,654 31 2,371
 
3 mo
 
ND  0 0 ND 34 ND
 
7 mo
 
ND  0 5 21,555 29 2,354
The ages at which env genes were amplified from infant viral isolates for cloning and insertion into vv are denoted in bold type.
 
*
 
TCID
 
50
 
/ml plasma.
 
‡
 
TCID
 
50
 
/10
 
6
 
 PBMC.
 
§
 
RNA copies/ml plasma. 
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cultured in complete media (CM) containing RPMI, 10% FCS,
50 
 
m
 
g/ml gentamicin, and 5 U/ml IL-2 were pelleted, resus-
pended in 1 ml of viral culture supernatant, and incubated for 1 h
at 37
 
8
 
C in 5% ambient CO
 
2
 
. The cells were then washed and re-
suspended in CM; the p24 antigen content of the supernatant was
monitored daily by enzyme immunoassay. On day 5 of culture,
high molecular weight DNA was purified by a standard protein-
ase K digestion–isopropanol precipitation technique.
 
PCR Primers and Conditions.
 
Oligonucleotide primer sequences
were chosen from regions directly upstream and downstream of
the initiation and termination codons of the 
 
env
 
 gene, respec-
tively. The following two primers were used: MNA, 5
 
9
 
-GCG-
AAAGAGCAGAAGACAGTGGC-3
 
9
 
 (corresponding to positions
6197–6220 of the NL4-3 genome) and MN13, 5
 
9
 
-CAGCTC-
GTCTCATTCTTTCCC-3
 
9
 
 (positions 8836–8857). PCR mix-
tures consisted of 10 mM Tris (pH 8.3), 50 mM KCl, 0.2 mM
each of the four deoxynucleoside triphosphates, 2.5 mM MgCl
 
2
 
,
10 pmol of each primer, 200 ng of DNA, and 2.5 U of ampliTaq
polymerase (Perkin-Elmer, Foster City, CA), which was added
during an initial 3-min denaturation step. Amplification was con-
ducted for 30 cycles in a thermal cycler (Perkin-Elmer). Each cy-
cle consisted of three steps: denaturation (94
 
8
 
C for 60 s), primer
annealing (60
 
8
 
C for 90 s), and extension (72
 
8
 
C for 3 min), with a
final extension at 72
 
8
 
C for 10 min.
 
Heteroduplex Formation and Sequence Diversity Determination.
 
The
V1 to V3 region of 
 
env
 
 was PCR amplified from the cloned PCR
env products using primers 209 (positions 6453–6470) and 218
(positions 7382–7399). PCR conditions were identical to those
described above except for a MgCl
 
2
 
 concentration of 4 mM, an
annealing temperature of 55
 
8
 
C, and the absence of a hot start. Af-
ter the internal labeling of PCR products with [
 
32
 
P]dCTP, het-
eroduplexes were formed between labeled and unlabeled products
and DNA fragments were separated in a neutral 5% polyacrylamide
gel (12). DNA fragments were separated using the Model S2 Se-
quencing Gel Electrophoresis Apparatus (GIBCO BRL, Gaithers-
burg, MD) at 30 mA for 12 h. Sequence comparisons and diver-
sity estimates were determined using best-fit analysis in GCG
using the Genetics Computer Group’s Wisconsin Sequence Anal-
ysis Package version 8.0.1 with the use of the default program pa-
rameters.
 
Molecular Cloning and Recombinant vv Generation.
 
The entire 2.6-
kb coding region of env was PCR amplified from proviral DNA
at each of two early timepoints (first and 3–6-mo isolates) from
each patient; the PCR product was gel purified with Eluquick
(Schleicher & Schuell, Keene, NH) and ligated to the plasmid
vector pCR3 (InVitrogen, San Diego, CA). After ligation, the
reaction mixture was introduced into TOP10F
 
9
 
 cells by CaCl
 
2
 
transformation. Cells were plated on LB–carbenicillin agar plates
and incubated overnight at 37
 
8
 
C; selected colonies were then ex-
panded in 3-ml cultures containing LB–ampicillin overnight at
37
 
8
 
C. Clones with inserts of appropriate size, as judged by restric-
tion enzyme digestion, were sequenced at the SP6 or T7 pro-
moter sites within pCR3 adjacent to the insert to determine ori-
entation using the Sequenase Version 2.0 sequencing kit (United
States Biochemicals, Cleveland, OH). Clones were then grouped
according to digestion patterns obtained with StuI, AvaI, BamHI,
KpnI BglI, and HindIII and a predominant clone was selected
from each timepoint for subcloning (Table 2).
 
Table 2.
 
Grouping of Patient Isolate env Clones within pCR3 Based upon Restriction Digests and Choice of Predominant Clones for 
Preparation of vv
 
Patient Age Group Env clones
 
*
 
Recombinant vv
VI-05 2 mo 05-2M-A 3-2, 
 
3-4
 
, 3-5, 3-7, 3-8, 3-10 vvVI-05-2M
05-2M-B 3-3
6 mo 05-6M-A
 
4-2
 
, 4-4, 4-5, 4-6, 4-8, 4-9 vvVI-05-6M
VI-06 Birth (1 d) 06-1D-A 1-2, 1-3
06-1D-B 1-9
06-1D-C 1-11, 1-12, 
 
1-13
 
, 1-15, 1-20 vvVI-06-ID
06-1D-D 1-18
6 mo 06-6M-A 2-1, 2-2, 2-3, 2-4, 2-7, 2-8, 2-9, 2-10
 
‡
 
06-6M-B 2-5
 
‡
 
VI-08 20 d 08-20D-A 5-4
08-20D-B 5-6
08-20D-C
 
5-2
 
, 5-3, 5-8, 5-9, 5-10 vvVI-08-20D
6 mo 08-6M-A 6-1
08-6M-B
 
6-2
 
, 6-3, 6-4, 6-7, 6-8, 6-9, 6-10 vvVI-08-6M
VI-11 1 mo 11-1M-A 7-1
11-1M-B 7-2, 7-5, 7-7, 7-10, 
 
7-11
 
, 7-16, 7-19 vvVI-11-1M
11-1M-C 7-12
3 mo 11-3M-A 8-3
11-3M-B
 
8-4
 
, 8-11, 8-14, 8-16 vvVI-11-3M
 
*
 
env genes amplified by PCR and ligated into pCR3 (InVitrogen); clones chosen for preparation of vv are in bold type.
 
‡
 
vv not made from this time point due to instability of the env insert. 
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The predominant clone from each timepoint was digested
with BamHI and XhoI and ligated into the BamHI–XhoI site of
pAbT4587A (created by the addition of an XhoI site within the
pAbT4587 vector provided by Therion Biologics, Cambridge,
MA). After ligation, the reaction mixture was introduced into
DH5a cells (Therion Biologics, Cambridge, MA) by CaCl
 
2
 
 trans-
formation. Cells were grown as described above and clones were
again screened by restriction enzyme digests.
Recombinant vv expressing infant isolate 
 
env
 
 gene products
were generated, amplified, and titered according to the methods
of Mazzara et al. (13). Each env-recombinant vv expressed gp160
and its cleavage products as determined by radio immunoprecipi-
tation. In addition, each of these vv was able to sensitize target
cells to antibody-dependent cell-mediated cytotoxicity (ADCC)
lysis (Pugatch, D., K. Luzuriaga, and J.L. Sullivan, manuscript
submitted for publication).
 
Limiting Dilution Assays of CTL Precursors.
 
HIV-1 env-specific
CTLp frequencies were estimated using previously described meth-
ods (4, 14). To minimize potential variability in assay conditions
and to allow comparison of results between the timepoints stud-
ied for each infant, all limiting dilution cultures for each infant
were set up and all CTLp assays were performed at the same time
and with the same reagents. Cryopreserved PBMC were thawed
and diluted at 16,000 to 250 lymphocytes per well in 24 replicate
wells of 96-well microtiter plates; 2.5–5.0 
 
3
 
 10
 
4
 
 irradiated PHA
blasts from HIV-1–uninfected donors and mAb to CD3 (12 F6;
0.1 
 
m
 
g/ml; provided by Dr. J.T. Wong, Massachusetts General
Hospital, Boston, MA) were added to each well and the plates
were incubated at 37
 
8
 
C in R10 with 30 U/ml IL-2 for 7–10 d.
Wells were then split and assayed for cytotoxicity on 
 
51
 
Cr-labeled
autologous B lymphoblastoid cell lines infected either with vac
alone or with vv-expressing IIIB or patient isolate env proteins
(M.O.I. 
 
5
 
 5:1). The fraction of nonresponding wells was defined
as the number of wells in which lysis did not exceed 10% (VI-11)
or 20% (VI-05, VI-06, VI-08). Percentage of lysis was calculated
for each well using the formula 100 
 
3
 
 (test cpm 
 
2
 
 spontaneous
cpm) / (maximal cpm 
 
2
 
 spontaneous cpm); the CTLp frequency
and 95% confidence limits were calculated using the maximum
likelihood method (15) and a spreadsheet provided by Dr. S. Kalams
(Massachusetts General Hospital, Boston, MA). Split well analysis
was used to examine the cross-reactivity of CTLp.
 
Quantitation of Plasma HIV-1 RNA.
 
Plasma HIV-1 RNA levels
were measured after reverse transcription and PCR amplification
using a commercial assay (Roche Diagnostic Systems, Branchburg,
NJ), as directed by the manufacturer.
 
Results
 
HIV-1 Infant Isolate env Sequences Are Homogeneous and
between 8–10% Divergent from IIIB env.
 
We began by ex-
amining the degree of diversity between infant isolate env
and IIIB env. Examination of sequences through the V3
loops suggested relative homogeneity of first isolates (data
not shown). Divergence in nucleotide sequence between
HIV-1 IIIB and individual infant isolate env was then esti-
mated using heteroduplex tracking assays and sequencing.
Fig. 1 demonstrates that heteroduplexes formed by com-
bining individual infant isolate and IIIB env migrate at rates
between those of heteroduplexes formed by combining
IIIB and MN env or IIIB and p08-6-20D (an env clone
derived from the virus of patient VI-08). Sequence com-
Figure 1. Heteroduplex analysis of homology between patient isolate
DNA and IIIB env sequences. Env fragments (946 bp in the V1-V3 re-
gions) were PCR amplified from genomic DNA extracted from PBMC
infected with patient HIV-1 isolates or from a plasmid containing BH10
(IIIB) env (pAbT4603). The PCR product of pAbT44603 was internally
radiolabeled during the PCR and combined with the PCR products of
the proviral templates of the patient to form heteroduplexes as described
in Materials and Methods. Lanes 1–3 are clones of known sequence
probed with pAbT4603. Lane 1 is a PCR product of the NL 4-3 strain of
HIV-1, lane 2 is a PCR product of the MN strain of HIV-1 (prototypic
clade B strain of HIV-1), and lane 3 is a PCR product from an env clone
derived from patient VI-08 at 1 d of age (pJA-6-1D). Lanes 4–11 are
PCR products amplified from patient proviral DNA (VI-06-1D and VI-06;
VI-05; VI-05-6M; VI-08-20D and VI-08-6M; VI-11-1M and VI-11-3M;
Table 2). Lane 12 is a negative control of probe alone. 
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parisons of a 946-bp region spanning V1 to V3 indicate
that IIIB and MN env differ from each other by 8.3%,
whereas IIIB and p08-6-20D differ by z10%. Therefore,
the degree of heterogeneity between individual infant iso-
late and IIIB env sequences is between 8–10%.
The Generation of Recombinant vv from Early Infant Viral
Isolates. The entire 2.6-kb coding region of env was am-
plified from proviral DNA at two early timepoints (and first
3–6-mo isolates) from each infant, ligated into pCR3 (In-
Vitrogen), and digested with StuI, AvaI, BamHI, KpnI,
BglI, and HindIII. One to four distinct patterns of restric-
tion digests were obtained from each set of clones derived
from virus from each patient at a single timepoint and were
designated as groups A, B, C, and D. The group containing
the largest number of clones was considered to be the pre-
dominant group and one clone was then chosen from each
predominant group for subcloning (Table 2). The instabil-
ity of the env gene from the viral isolate of patient VI-06 at
6 mo of age in pAbT4587A prevented its subcloning.
Therefore, only one env subclone, from 1 d of age, was de-
rived from virus of infant VI-06.
The gel isolation of multiple env genes for subcloning
could potentially result in contamination of one env gene
with another. Heteroduplex analysis was employed to as-
certain whether the subcloned envs were identical to the
original clone from which they were derived. Absence of
contaminating env sequences was shown by the lack of het-
eroduplex formation between cloned env fragments and
their identical subclone (Fig. 2). In addition, env coding se-
quences from pNL4-3, a molecular clone used frequently
in our laboratory, were also used to form heteroduplexes
with the env clones derived from infant viral isolates to en-
Figure 2. Heteroduplex analysis of cloned and sub-
cloned env genes. env fragments (946 bp in the V1–V3
regions) were PCR amplified from env clones within
the pCR3 and pAbT4587A backbones and from
pNL4-3. The PCR product of env clones within
pCR3 and pNL4-3 were internally radiolabeled during
the PCR. The PCR products of env clones within
pCR3 were combined with the PCR products of the
identical env subclones within pAbT4587A to form
heteroduplexes as described in Materials and Methods.
The radiolabeled PCR product of pNL4-3 was also
combined with PCR products of the env clones within
pAbT4587A to form heteroduplexes. Lanes 1–7 are
subcloned  env genes probed with identical genes ligated
into pCR3. Lanes 8–14 are subcloned patient isolate
env genes probed with pNL4-3. Lanes 15–22 are nega-
tive controls containing radiolabeled PCR products
alone.1158 Type versus Group-specific CTL in Early Vertical HIV-1 Infection
sure that none contained the pNL4-3 env sequence. The
formation of heteroduplexes of varying mobility between
pNL4-3 and the cloned env fragments further verified lack
of contamination and demonstrated that each of the env
clones was unique.
HIV-1 env-specific CTL Responses in Early Infancy. Begin-
ning in early infancy, CTLp frequencies were measured se-
quentially in the peripheral blood of the four infants stud-
ied. In three infants, env-specific CTLp were detected by 6
mo of age (Table 3).
HIV-1–specific CTLp recognizing autologous env gene
products were detected in the peripheral blood of a second
infant (VI-11) at 3, 7, and 12 mo of age and preceded the
first detection of CTLp recognizing HIV-1 IIIB env gene
products at 12 mo of age (Table 3). HIV-1–specific CTLp
recognizing first (20-d) isolate and IIIB env gene products
were detected by 4 mo in another intrapartum-infected in-
fant (VI-08). In infant VI-06, HIV-1–specific CTLp recog-
nizing first isolate and IIIB env gene products were detected
by 6 mo of age. HIV-1–specific CTLp were not detected
in the cord blood of infant VI-05, but CTLp recognizing
IIIB and infant isolate env gene products were detected at
12 mo of age.
Evaluation of Cross-reactivity of HIV-1 env-specific CTLp
Using Split-well Analysis. Genotypic analysis of sexually (16)
and vertically (6, 7) transmitted HIV-1 strains suggests that
limited viral genotypes appear to be transmitted or ampli-
fied after infection. After infection, diversification of viral
species may occur through reverse transcriptase error and
various selective pressures (for review see reference 17).
New populations of CTL may expand in an infected indi-
vidual in response to evolving quasispecies of HIV-1, resulting
in a broadening of the HIV-1 immune response. Split-well
analysis allowed us to examine CTLp cross-reactivity on a
clonal level. Fig. 3 illustrates CTLp cross-reactivity over time.
HIV-1 env-specific CTLp detected in VI-11 in early in-
fancy exclusively recognized early infant isolate env, whereas
HIV-1–specific CTLp detected in later infancy were pri-
marily cross-reactive. In VI-06 and VI-08, cross-reactive
CTLp recognizing early infant isolate and IIIB env were
detected as early as 6 and 4 mo of age, respectively. At 6
mo of age, only CTLp recognizing target cells infected with
vv expressing the 20-d isolate were detected in VI-08, while
cross-reactive CTLp were detected again at 19 mo. Since
virus-independent in vitro stimulation was used to expand
CTLp, the CTLp frequencies detected are likely reflective
of the CTLp frequencies in vivo. However, at the relatively
low CTLp frequencies detected at 6 mo, sampling error
might explain the sole detection of type-specific CTLp.
HIV-1-specific CTLp Activity Detected in Early Infancy Is
CD8 T Cell Mediated. HIV-1 env-specific cytolysis may be
CD8 T cell mediated and HLA class I–restricted or NK
cell–mediated cytolysis through ADCC (18). Unfortu-
nately, the limited PBMC repository available from early
infancy precluded the use of CD4, CD8, or NK-depleted
PBMC populations in the limiting dilution assays. To de-
termine the phenotype of the effector cells in the limiting
dilution assays, we performed limiting dilution assays in
which a bispecific (anti-CD3, CD8) mAb was used instead
of mAb to CD3 (19). Use of this antibody led to the deple-
tion of CD8 T cells from the LDA wells (,1% CD8 T cells
compared with 45% CD8 T cells in the wells treated with
Table 3. HIV-1 env-specific CTLp Frequencies Over Time
CTLp (95% confidence intervals)
Patient vv* Cord blood 2 mo 4 mo 6 mo 7 mo 12 mo 19 mo
VI-06 vac 34 (23–50) 0.5 (0.03–8)
IIIB 13 (7–23) 153 (118–200)
vvVI-06-1D 64 (47–87) 197 (151–257)
VI-05 vac 3 (1–10) 65 (48–89)
IIIB 3 (1–9) 219 (169–284)
vvVI-05-2M 8 (4–17) 129 (99–168)
vvVI-05-6M ND 55 (40–76)
VI-08 vac 88 (66–116) 50 (36–70) 19 (12–32)
IIIB 240 (184–311) 50 (35–70) 201 (154–262)
vvVI-08-20D 165 (127–213) 130 (99–170) 81 (60–108)
vvVI-08-6M 202 (156–261) 80 (60–107) 175 (135–229)
VI-11 vac 8 (4–17) 3 (1–10) 95 (72–125)
IIIB 23 (14–36) 4 (1–11) 286 (219–373)
vvVI-11-1M 136 (105–177) 42 (29–60) 537 (403–717)
vvVI-11-3M 138 (107–180) 70 (52–94) 233 (180–303)
*vac, vaccinia alone; IIIB, vv expressing IIIB env gp160. See Table 2 for explanation of vaccinia vectors expressing infant isolates.1159 Pikora et al.
mAb to CD3 alone) and a 55–90% reduction in env-spe-
cific CTLp frequency compared with wells treated with mAb
to CD3 alone. These studies suggest that the env-specific
CTLp detected in the assays were mediated by CD8 T cells.
Detection of HIV-1 Env-specific CTLp in Early Vertical Infec-
tion, Viral Load, and Clinical Disease Progression. In three infants,
HIV-1–specific CTL recognizing early infant isolate gene
products were detected before 6 mo of age. Infant VI-11,
in whom HIV-1 gag- and early isolate env-specific CTL
were detected by 3 mo of age, has remained only mildly
symptomatic without evidence of immune suppression
(CDC A1; reference 20) at 3 yr of age. However, as previ-
ously described (4), infant VI-06 experienced a rapid in-
crease in viral load and a rapid decline in peripheral blood
CD4 T cell numbers after birth despite the detection of
HIV-1 gag- and env-specific CTL in cord blood and 3-wk
specimens. While env-specific CTLp were detected in in-
fant VI-08 by 4 mo of age, this infant developed HIV-1
encephalopathy and severe CD4 depletion (CDC C3) by 3
yr of age. The early detection of HIV-1 env-specific CTLp
in the latter two infants suggest that HIV-1–specific CTL
alone may not protect against CD4 depletion or disease pro-
gression.
Discussion
In assays using target cells expressing laboratory strain HIV-1
gene products, HIV-1–specific CTLp have been uncom-
monly detected in early infancy. This study addressed the
hypothesis that type-specific responses might predominate
in early infancy and that the use of target cells expressing
laboratory isolate gene products might limit the detection
of HIV-1–specific CTL in early infancy. To address this
hypothesis, HIV-1 env genes from early isolates of four ver-
tically infected infants were PCR amplified, cloned, and
used to generate recombinant vv. The frequencies of CTLp
recognizing target cells infected with vv-expressing env
gene products from early isolates and HIV-1 IIIB were se-
rially measured from early to late infancy using limiting di-
lution followed by in vitro stimulation with mAb to CD3.
HIV-1–specific CTLp were detected before 6 mo of age in
three infants. In one infant, the detection of CTLp recog-
nizing target cells expressing early isolate env preceded the
detection of CTLp recognizing target cells expressing IIIB
env; these type-specific CTLp detected in early infancy
were later replaced by cross-reactive group-specific CTL. In
two other infants, early group-specific responses were de-
tected. In a fourth infant, CTLp recognizing target cells in-
fected with HIV-1 IIIB env and early isolate env were simul-
taneously detected at 12 mo of age. These results reconfirm
that young infants can generate HIV-1–specific CTL re-
sponses and provide support for the concept of perinatal
vaccination to prevent HIV-1 transmission.
The generation of vv-expressing infecting strain gene prod-
ucts was central to our studies. To minimize the chance of
amplifying defective HIV-1 env sequences, we chose to
use  env genes amplified from cultured virus to construct the
env-expressing recombinant vv. Whereas several studies have
demonstrated the outgrowth of variant strains of limited di-
versity in viral coculture that did not predominate in vivo
at the timepoint at which the culture was established (21,
22), several lines of evidence suggest that the isolates used
were representative of the in vivo population of viruses.
First, studies that have compared the selection of variants in
culture to those present in vivo have maintained these viral
cultures up to at least 28 d. The env genes used to generate
recombinant vv in our studies were amplified from mini-
mally passaged virus cultured for less than 1 wk. Second,
the absence of anti-retroviral therapy in these patients at
each of the timepoints from which the env vaccinia recom-
binants were generated supports the notion that these vari-
ants were not suppressed in vivo and expanded in vitro in
the absence of drug. Third, the ability of CTL precursors
from these patients to recognize env protein products from
the env sequences derived from cultured virus suggests that
these sequences were present in vivo.
Minimal diversity in env sequences of HIV-1 strains iso-
lated from adults and infants early in primary infection has
Figure 3. Evaluation of env-specific CTLp cross-reactivity using split-well analysis. Proportional CTLp frequencies at each designated time are summa-
rized as Venn diagrams. See Tables 1 and 2 for descriptions of patients and vv-expressing infant isolates.1160 Type versus Group-specific CTL in Early Vertical HIV-1 Infection
been reported (6, 7, 16). Although HIV-1–specific CTL
expand in response to a homogeneous population of vari-
ants in both populations of infected individuals, group-spe-
cific CTL appear to be detected more commonly in adult
primary infection than in vertical primary infection (23,
24). Therefore, the type specificity of early infant CTL re-
sponses is not likely due to a homogeneous starting popula-
tion of virus.
Adults possess memory CTL that may cross-react with
HIV-1 proteins and expand in response to HIV-1 infection
in concert with antigen-naive CTL precursors. CTL ex-
pansion upon acute HIV-1 infection in adults may be simi-
lar to that observed by Selin et al. (8) in mice. They ob-
served that acute Pichinde virus infection in LCMV
immune mice resulted in expansion of CTL that were
cross-reactive with both LCMV and Pichinde virus. Cross-
reactive memory CTL originally expanded in response to a
previous non–HIV-1 antigenic encounter may possess
TCRs with lower affinity for HIV-1 antigen. A lower af-
finity interaction may allow for a greater degree of promis-
cuity in recognition of epitopes of HIV-1 gene products on
various HIV-1 strains. The group-specific CTL responses
detected in infected adults during or shortly after serocon-
version may be due in part to the contribution of this ex-
panded non–HIV-1–specific memory pool of CTL.
In contrast, HIV-1 infection occurs in infants whose im-
mune systems have not been primed by previous antigenic
exposure. Therefore, potentially cross-reactive memory
CTL may not exist. Diversification of the viral variant pop-
ulation over time may eventually result in the expansion of
CTLp populations recognizing a greater number of viral
epitopes with the concomitant ability to recognize these
epitopes on more than one strain of HIV-1.
Alternatively, type-specific responses detected in some
young HIV-1 vertically infected infants may be due to par-
tial tolerance. Vertical HIV-1 infection occurs at a time
when the cellular immune system is being vigorously ed-
ited on the basis of its ability to discriminate between self
and nonself. HIV-1 antigen may be viewed as self-antigen
during this process and HIV-1–reactive CTL may be de-
leted or anergized. The ability of HIV-1 to infect and rep-
licate within professional antigen presenting cells such as
macrophages and its presence on dendritic cells may allow
for activation of a small population of HIV-1–reactive CTL
that escape tolerance induction. This partial break in toler-
ance may originally be directed at a limited array of viral
epitopes, resulting in a type-specific CTL response. Recog-
nition of these initial epitopes by CTL may lead to an ex-
pansion of CTL responsiveness in which a progressively
greater number of viral epitopes may be recognized. Ex-
pansion in epitope recognition may subsequently result from
the phenomenon of epitope spreading (25) in concert with
a diversification of HIV-1 variants toward viral gene prod-
ucts whose sequences bear less resemblance to the original
tolerizing variants. The group-specific CTL responses de-
tected by 12 mo of age may evolve in this manner.
In summary, our studies indicate that young infants are
capable of generating virus-specific CTL in response to viral
infection and some support the development of a neonatal
HIV-1 vaccine. However, the detection of type-specific
immunity in some young infants suggests that a vaccine
based upon laboratory strains of HIV-1 may not be protec-
tive. For optimal efficacy, it will likely be necessary to use
gene products from viral strains isolated from patients in
targeted geographical regions as immunogens.
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